EULAR: EULAR 2018: key pipeline developments in psoriatic arthritis
Inteleukin-23 (IL-23) inhibitors have made a name for themselves in the treatment of psoriasis (PsO) following the launch of J&J's...Read More...The post EULAR 2018: key pipeline developments in psoriatic arthritis appeared first on Pharmaceutical Technology.
Read full article »
CEO
EULAR is a Private company. EULAR generates $8.3K in revenue per employee EULAR has 1 followers on Owler.